Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Hepion Pharmaceuticals Inc (HEPA)

Hepion Pharmaceuticals Inc (HEPA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,410
  • Shares Outstanding, K 6,958
  • Annual Sales, $ 0 K
  • Annual Income, $ -48,930 K
  • EBIT $ -25 M
  • EBITDA $ -22 M
  • 60-Month Beta 1.63
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.38
  • Most Recent Earnings $-0.72 on 11/14/24
  • Next Earnings Date 11/18/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4777 +2.57%
on 12/11/24
0.7200 -31.94%
on 11/21/24
-0.2043 (-29.43%)
since 11/20/24
3-Month
0.4777 +2.57%
on 12/11/24
0.8900 -44.94%
on 10/17/24
-0.2090 (-29.90%)
since 09/20/24
52-Week
0.4777 +2.57%
on 12/11/24
3.7200 -86.83%
on 12/26/23
-2.4400 (-83.28%)
since 12/20/23

Most Recent Stories

More News
Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.

HEPA : 0.4900 (-7.37%)
Hepion Pharmaceuticals Urges Shareholders to Approve Merger with Pharma Two B to Enhance Investment Potential

Hepion Pharmaceuticals urges shareholders to support its merger with Pharma Two B to enhance investment potential and address financial challenges.Quiver AI SummaryHepion Pharmaceuticals is urging its...

HEPA : 0.4900 (-7.37%)
Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B

HEPA : 0.4900 (-7.37%)
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger

HEPA : 0.4900 (-7.37%)
Hepion Pharmaceuticals (NASDAQ: HEPA) Reports Promising Phase 2 Trial Results for NASH Treatment

Renocofilstat's Positive Outcomes Reinforce Antifibrotic Action Hepion Pharmaceuticals, a clinical stage biopharmaceutical company focusing on AI-assisted therapeutic drug development, recently

HEPA : 0.4900 (-7.37%)
Pre-Market Brief: Stocks Mostly Higher As Investors Await U.S. Inflation Data

March S&P 500 futures (ESH23) are trending up +0.32% this morning after three major U.S. benchmark indices finished the regular session higher as market participants awaited U.S. inflation data for further...

ESH23 : 3,957.05s (-0.09%)
JD-.LN : 95.450 (-1.70%)
HEPA : 0.4900 (-7.37%)
BWEN : 1.8500 (+3.35%)
PROK : 1.5100 (+3.42%)
CONN : 0.0975 (-46.40%)
SHC : 13.24 (-0.23%)
STM : 24.61 (+0.53%)
Hepion Pharmaceuticals Announces Further Adjournment of Annual Meeting of Stockholders

EDISON, N.J., July 22, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on...

HEPA : 0.4900 (-7.37%)
Hepion Pharmaceuticals Further Strengthens Board with Appointments of Accomplished Biopharmaceutical Executives, Mr. Anand Reddi and Dr. Kaouthar Lbiati

EDISON, N.J., June 28, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on...

HEPA : 0.4900 (-7.37%)
Hepion Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders

EDISON, N.J., June 24, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on...

HEPA : 0.4900 (-7.37%)
Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of Hepatocellular Carcinoma

EDISON, N.J., June 20, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on...

HEPA : 0.4900 (-7.37%)

Business Summary

Hepion Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. It is focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis and chronic hepatitis virus infection. The Company's lead drug candidate CRV431, reduces liver fibrosis and hepatocellular...

See More

Key Turning Points

3rd Resistance Point 0.5699
2nd Resistance Point 0.5499
1st Resistance Point 0.5200
Last Price 0.4900
1st Support Level 0.4701
2nd Support Level 0.4501
3rd Support Level 0.4202

See More

52-Week High 3.7200
Fibonacci 61.8% 2.4814
Fibonacci 50% 2.0989
Fibonacci 38.2% 1.7163
Last Price 0.4900
52-Week Low 0.4777

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar